HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是确定是否可以从正在接受联合抗HIV治疗的HIV感染患者中收集外周血祖细胞（可以成为血细胞的未成熟细胞）。这些细胞将在非霍奇金淋巴瘤（NHL）或霍奇金病（HD）的高剂量化疗后返回给研究参与者。其他目的是评估这种治疗的副作用，并估计无病生存期和总生存期。hiv相关NHL/HD患者在常规化疗和/或放疗的情况下预后非常差。虽然可以达到缓解（没有可检测到的淋巴瘤），但缓解的持续时间通常很短。最近的研究表明，患有NHL/HD但没有HIV感染的人接受高剂量化疗以努力摧毁任何剩余的NHL/HD可以获得长期缓解。然而，这种强化疗法也会破坏正常的骨髓细胞。为了减少这个问题，可以在化疗过程中收集患者的外周血祖细胞（PBPC），在强化治疗结束后静脉注射（通过静脉）给患者。这个过程被称为自体PBPC移植。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine whether peripheral blood progenitor cells (immature cells that can become blood cells) can be collected from patients with HIV infection who are being treated with combination anti-HIV therapy. These cells will be given back to research participants after high dose chemotherapy for non-Hodgkin's lymphoma (NHL) or Hodgkin's Disease (HD). Additional purposes are to evaluate the side effects of this treatment and estimate the disease-free and overall survival. The prognosis of patients with HIV-related NHL/HD is very poor with conventional chemotherapy and/or radiotherapy. Although remission (absence of detectable lymphoma) can be achieved, the duration of remission usually is short. Recent studies have shown that persons who have NHL/HD but no HIV infection who receive high dose chemotherapy in an effort to destroy any remaining NHL/HD can achieve long-term remission. However, this type of intensive therapy also destroys normal marrow cells. To help reduce this problem, the patient's peripheral blood progenitor cells (PBPC) can be collected part way through chemotherapy to be returned to the subject intravenously (through a vein) after the intensive therapy is over. This procedure is called autologous PBPC transplantation.